UB-311 Vaccine Safe in Mild Alzheimer’s Patients, Phase 2a Trial Shows

UB-311 Vaccine Safe in Mild Alzheimer’s Patients, Phase 2a Trial Shows
United Neuroscience’s vaccine candidate UB-311 was safe and well-tolerated in patients with mild Alzheimer's disease, according to results from a Phase 2a clinical trial. Patients who participated in this trial are now eligible to enroll in a long-term follow-up study that will continue to assess the vaccine’s safety for 108 weeks. Trial results, “Active Immunotherapy with UB-311 vaccine: Results from a Phase IIa, randomized, double-blind, placebo-controlled, 3-arm parallel-group, multicenter study” were recently presented during the 14th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Lisbon, Portugal. UB-311, developed by United Neuroscience, a spin-off of United Biomedical, is a synthetic peptide vaccine that triggers an antibody response against beta-amyloid — whose accumulation in the brain is a hallmark of Alzheimer’s disease — clearing it away without causing potentially harmful inflammation. Results from a Phase 1 trial (NCT00965588) showed that UB-311 was safe and well-tolerated, and able
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *